The exploitation of natural resources and the improper use and disposal of thousands of chemicals have resulted in environmental pollutionand a potential threat to human health on a global scale. Increasing public concern about environmental exposure to and consequent ill health from contaminants demands informed answers based on valid risk assessment. By assessing internal exposure to pollutants, human biomonitoringfocuses on early markers of potential risks to prevent serious adverse effects. Exposure assessment may provide a rational basis for risk assessment, with knowledge of the adequacy of limitvalues; it may also uncover long-term changes in body burdens and thus help identifythe sources and transfer pathways of environmental pollutants. Exposure assessmenL-Process of measuring or estimating concentration or intensity, duration, and frequency of exposures to an agent present in the environment or, if estimating hypothetical exposures, that might arise from the release of a substance, or radionucleide, into the environment.
Indexing Terms: toxicology/biomonitoring/environmentai hazards
Exposure assessmenL-Process of measuring or estimating concentration or intensity, duration, and frequency of exposures to an agent present in the environment or, if estimating hypothetical exposures, that might arise from the release of a substance, or radionucleide, into the environment.
Exposure.-Concentration, amount, or intensity of a particular physical or chemical agent that reaches the target population, organism, organ, tissue, or cell, usually expressed in numerical terms of substance concentration, duration, frequency and for physical agents, intensity.
Biological monitoring: Continuous or repeated measurement of potentially toxic substances or their metabolites or biochemical! physical effects in tissues, secreta, excreta and expired air in order 
Exposure Assessment
The traditional approach (3, 4) distinguishes between monitoring of external and internal exposure and biological effects ( Table 1) . External exposure can be described by route, magnitude, duration, and frequency; internal exposure, by the amount recently absorbed (recent exposure), the amount accumulated and stored in the body (body burden), and the amount of an active chemical bound to specific sites of action (target dose). Exposure assessment takes place in a continuum ranging from sources and route (dose) to measurement of a specific compound or metabolites in a biological specimen, to effect markers and disturbed body function and to early signs of the resulting disease(s) (5).
The relation between external exposure (dose) and effect can be viewed as a chain of different interrelated levels (6) (Fig. 1) . However, the distinction between these levels and between nonadverse, adverse, or subclinical and clinical effects is not always clear-cut. Individual susceptibility is a modifier of biological response and effects, as seen when uniformly exposed cohorts display a markedly different interindividual risk of adverse effects or disease (5). Susceptibffity markers are indicators for genetic or acquired factors (protective factors, repair and reserve capacity) influencing the probability of disease as a result of defined exposure.
Methods
The need for accurate exposure assessment has led to the application of analytical methods and pharmacokinetic techniques analogous to those adopted for pharmaceutical products in medical therapeutics, i.e., biometrics of exposure. 
Use of Biomarkers
External exposure Dose, pathway, frequency Specimens for human biomonitoring include urine and blood (whole blood, serum, plasma, cells), expired air, breast milk, body fat, keratinous and other selected tissue from biopsy or autopsy material, saliva, and excreta (feces, bile, sweat). Induced biochemical changes in the physiological or pathological components of an organism such as enzyme activity, metabolic intermediates, and early biological effects of exposure (e.g., covalent adducts and altered structure or function of a cell type or organ system) are examples of biological effect monitoring.
This type of monitoring can also be used if the relation between ambient exposure and effect is known.
Biomarkers
reflect the biological (nonadverse or adverse) response to exposures (5). For reactive compounds, covalent binding to certain proteins can be assessed by adducts (e.g., hemoglobin adducts) or on the subcellular levels by DNA adducts and other biological markers (7). The validity of some specific adducts has been proven and biological dosimetry is rapidly growing, although for environmental (low) exposure the ths-\ criminatory capability is limited (8) (9) (10) . Considerable \ developments have been made recently in the use of biomarkers for exposure assessment of environmental carcinogens at low doses and for correlating molecular doses, and their molecular effects.
Urine mutagenesis Thrombocyte function
Source: adapted from ref. However, in the same study, smoking was shown to produce the same pattern of DNA adducts. Smoking has marked effects on the expression of many biomarkers, and data must be controlled for smoking status.
Nonspecific markers are end points of exposure to different compounds, often indicating effects from multicompound exposure (e.g., air pollution, tobacco smoke) but unable to pinpoint the specific causative agent. Markers with low specificity are associated with exposure to certain classes of chemicals with similar toxicities, e.g., organophosphates
and cholinesterase inhibition, or those that are excreted as metabolites not unique to one compound, e.g., formaldehyde
and its metabolite formic acid, which also may come from other one-carbon compounds. Examples of marker specificity are given in Table 2 .
Most biomarkers are currently in the validation stage, but in future epidemiological studies they may indicate exposure and effect susceptibility (14). 
Application of Toxicokinetic Principles and interpretation
For selecting the correct marker of exposure, knowledge of the toxicokinetics of a compound or its marker is (29) . We have recently investigated in eight patients the circadian proffle of cadmium in urine (Fig. 3) and found nearly a twofold difference if an individual's sample was taken in the morning or late in the evening. Moreover, the circadian pattern did not parallel the excretion of creatinine and thus was not eliminated by creatinine normalization. For low-dose exposure, the influence of such fluctuations can be a source of variation and must be considered when comparing actual results with published data or reference intervals. For group outliers, reassay of another specimen aliquot is advised; however, such decisions must be based on statistically valid standardized procedures.
Normalization Procedures

Concentrations
Highly lipophilic compounds distribute into the bodyfat compartment, which is in equilibrium with blood lipids. Accordingly, expression of analytical results on the basis of fat rather than serum or blood concentration is essential. The usefulness of this normalization procedure is demonstrated by the fact that the influence of several variables on the blood PCB concentrations is abolished by standardization, although the influence of age remains (Table 6 ).
Interpretationof Results
Quite often, postanalytical errors in evaluation must also be considered.
Usually However, the validity and power of many biomarkers have yet to be proven for environmental exposures.
Without quantification of the dose-effect relation of a certain exposure and its outcome, the use of biomarkers will remain limited.
Needs in exposure assessment include (a) development of specific and sensitive markers of exposure, 
